NDAORALTABLET
Approved
Oct 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
4/8 — Partial
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SEYSARA (sarecycline hydrochloride) is an oral tetracycline-class antibiotic approved for treatment of acne vulgaris. It is a narrow-spectrum tetracycline with selective targeting of bacterial pathogens implicated in acne pathogenesis. The drug represents a modern formulation designed to improve tolerability and pharmacokinetic properties compared to earlier tetracyclines.
$0.658MPart D
Peak6.8 years to LOEProduct is at peak commercial maturity with stable but modest Medicare utilization; team likely focused on market penetration and cost-of-goods optimization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Comparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne.
Started Apr 2026
30 enrolled
Acne Vulgaris
Sarecycline Truncal Acne Safety and Efficacy Response
Started Mar 2021
10 enrolled
Acne Vulgaris
Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES)
Started Mar 2021
300 enrolled
Acne Vulgaris
Career Relevance
SEYSARA currently shows zero linked job openings in pharma career databases, reflecting stable mature-stage commercial operations. Career opportunities would center on brand management, field sales, and medical science liaison roles supporting acne dermatology segments.
Worked on SEYSARA at Almirall? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.